<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04989335</url>
  </required_header>
  <id_info>
    <org_study_id>RAC-002</org_study_id>
    <nct_id>NCT04989335</nct_id>
  </id_info>
  <brief_title>Bisantrene Combination for Resistant AML</brief_title>
  <official_title>An Open-label, Phase II, Two-stage, Study of Bisantrene(Xantrene) in Combination With Fludarabine and Clofarabine as Salvage Therapy for Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Race Oncology Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-label, Phase II, Two-stage, Study of Xantrene® (Bisantrene) in combination with&#xD;
      Fludarabine and Clofarabine as Salvage Therapy for Adult Patients with Relapsed or Refractory&#xD;
      Acute Myeloid Leukemia (AML) Lead-in stage: up to 12 (up to 2 cohorts in a 3+3 dose&#xD;
      escalation design) Efficacy stage: up to 17 (Simon 2-stage design 9+8)&#xD;
&#xD;
      Study Objectives:&#xD;
&#xD;
        -  Confirm safety and tolerability of the combination regimen&#xD;
&#xD;
        -  Time to response with combination treatment&#xD;
&#xD;
        -  Overall survival&#xD;
&#xD;
      The treatment regimen will comprise daily IV infusion of Fludarabine (Flu), Clofarabine (Clo)&#xD;
      and Bisantrene (Xan) administered via central venous line and controlled-rate infusion pump&#xD;
      with a 1-hour break between each agent infusion, amounting to a total of 6 hours for each&#xD;
      daily FluCloXan treatment in the following sequence:&#xD;
&#xD;
        -  First, infusion over 60 minutes of Fludarabine (Flu) at 10 mg/m2&#xD;
&#xD;
        -  Followed by infusion of Clofarabine (Clo) at 30 mg/m2 over 60 minutes&#xD;
&#xD;
        -  Followed by infusion of Bisantrene (Xan) at 250 mg/m2 over 2 hours. One cycle will&#xD;
           comprise daily IV infusion of the combination treatment course for 4 or 5 consecutive&#xD;
           days and rest period to between Day 30 and Day 42, based on patient performance and&#xD;
           disease status.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The recommended Phase 2 dose (RP2D) , assessed by the number of treatment days of FluCloXan</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The maximum tolerated dose (MTD) of Bisantre in mg per day</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate safety and tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The overall response rate (ORR)</measure>
    <time_frame>between Day 30 to Day 42.</time_frame>
    <description>Overall Response Rate (ORR) defined as the proportion of patients with complete remission (CR) and complete remission with incomplete blood count recovery (CRi) between Day 30 to Day 42.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.</measure>
    <time_frame>12 months</time_frame>
    <description>Confirm safety and tolerability of the combination regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of respons in months</measure>
    <time_frame>12 months</time_frame>
    <description>Number of months for each patient with no evidence of diseases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months</time_frame>
    <description>Median surviving months for each patients.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>MRD status</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the MRD status of patients post completion of FluCloXan. MRD will be asset in patients with defiant mutations by Polymerase Chain Techniques(PCR).</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Myelogenous Leukemia, Acute</condition>
  <arm_group>
    <arm_group_label>Bisantrene combined with Fludarabine and Clofarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bisantrene 250 mg at final concentration of 0.5 mg/mL will be administrated by intravenous (IV) infusion, delivered by a controlled-rate programmable pump via a central line over 2 hours.&#xD;
Fludarabine (generic) and Clofarabine (generic) are commercially available as injection for intravenous infusion.&#xD;
The treatment regimen will comprise daily IV infusion of Fludarabine (Flu), Clofarabine (Clo) and Bisantrene (Xan) administered via central venous line and controlled-rate infusion pump with a 1-hour break between each agent infusion, amounting to a total of 6 hours for each daily FluCloXan treatment in the following sequence:&#xD;
First, infusion over 60 minutes of Fludarabine (Flu) at 10 mg/m2&#xD;
Followed by infusion of Clofarabine (Clo) at 30 mg/m2 over 60 minutes&#xD;
Followed by infusion of Bisantrene (Xan) at 250 mg/m2 over 2 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisantrene</intervention_name>
    <description>Combined escalated dose chemotherapy</description>
    <arm_group_label>Bisantrene combined with Fludarabine and Clofarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Combined escalated dose chemotherapy</description>
    <arm_group_label>Bisantrene combined with Fludarabine and Clofarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>Combined escalated dose chemotherapy</description>
    <arm_group_label>Bisantrene combined with Fludarabine and Clofarabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written&#xD;
             Informed Consent and privacy language as per national regulations.&#xD;
&#xD;
          2. Age 18 -65 (inclusive) years&#xD;
&#xD;
          3. Diagnosis of AML by World Health Organization (WHO) classification (WHO, 2016) and&#xD;
             have received at least one line of therapy prior to enrollment into this study.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.0&#xD;
&#xD;
          5. Life expectancy ≥ 3 months.&#xD;
&#xD;
          6. Adequate organ function as evidenced by serum total bilirubin ≤ 2.0 mg/dL, alanine&#xD;
             aminotransferase (ALT) or aspartate aminotransferase (AST) ≤4 × the upper limit of&#xD;
             normal (ULN), serum albumin &gt;2.8 g/dL, serum creatinine ≤2 mg/dL.&#xD;
&#xD;
          7. Cardiac ejection fraction ≥50%, assessed by 2-Dimensional echocardiogram.&#xD;
&#xD;
          8. Pulmonary function ≥50% assessed by diffusing capacity for carbon monoxide (DLCO), and&#xD;
             any clinically significant decrease in DLCO must not be caused by infection.&#xD;
&#xD;
          9. Negative for serum markers for HIV, Hepatitis -B, -C, and HTLV-1&#xD;
&#xD;
         10. Clinically significant non-hematologic toxicity after prior chemotherapy has recovered&#xD;
             to Grade 1 per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.&#xD;
&#xD;
         11. Females must be surgically or biologically sterile or postmenopausal (amenorrhoeic for&#xD;
             at least 12 months) or if of childbearing potential, must have a negative urine or&#xD;
             serum pregnancy test within 14 days before study entry, and must agree to use an&#xD;
             adequate method of contraception, i.e. barrier method, during the study until 30 days&#xD;
             after the last treatment. Males must be surgically or biologically sterile or agree to&#xD;
             use an adequate method of contraception, i.e. barrier method, during the study until&#xD;
             30 days after the last treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute promyelocytic leukemia (APML, APL) M3 subtype of AML.&#xD;
&#xD;
          2. Other active malignancy (including other hematologic malignancies) or other malignancy&#xD;
             within the last 12 months except non-melanoma skin cancer or cervical intraepithelial&#xD;
             neoplasia.&#xD;
&#xD;
          3. Prior or current therapy:&#xD;
&#xD;
               1. Hydroxyurea or other oral medications to reduce blast count within 72 hours&#xD;
                  before the first dose of study drug&#xD;
&#xD;
               2. Treatment with an investigational agent within 14 days before the first dose of&#xD;
                  study drug, or not recovered from all acute effects of previous investigational&#xD;
                  therapy&#xD;
&#xD;
               3. Last treatment was with a drug of long elimination half-life (e.g. enasidenib),&#xD;
                  as such a wash out period 5x elimination half-life is necessary prior to&#xD;
                  enrollment&#xD;
&#xD;
          4. For patients who have undergone hematopoietic stem cell transplantation (HSCT),&#xD;
             procedure-related medications (e.g. immunosuppressive therapy) administered within 2&#xD;
             weeks prior to first dose of study drug.&#xD;
&#xD;
          5. Any medical, psychological, or social condition that may interfere with study&#xD;
             participation or compliance or may compromise the patient's safety in the opinion of&#xD;
             the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnon Nagler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arnon Nagler, MD</last_name>
    <phone>972-3-530-58-30</phone>
    <email>Arnon.Nagler@sheba.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>57261</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnon Nagler, M.D.</last_name>
      <phone>+97235305830</phone>
      <email>Arnon.Nagler@sheba.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>M.D.</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Prof Arnon Nagler</investigator_full_name>
    <investigator_title>Director Hematology Division</investigator_title>
  </responsible_party>
  <keyword>AML, Resistance relapsing ,Anti Leukemic effect , Bisantrene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Bisantrene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

